Buying guide
Lingo vs Apple Watch in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | Abbott | Apple |
| Form factor | biometric | biometric |
| Maturity | commercial | commercial |
| Availability | shipping-nowshipping | shipping-nowshipping |
| Price | $54 (actual sale price) | $399-$799 (actual sale price) |
| Capability claims | — |
|
| Brain | — | — |
| Verified deployments | 1Abbott | 1Apple |
| Privacy practices | 4third-party-sharing, data-deletion-control, biometric-storage, training-data-use | 13cloud-upload, third-party-sharing, location-tracking, on-device-processing, training-data-use, data-sale, data-retention, biometric-storage, data-deletion-control, data-sale, data-deletion-control, data-retention, biometric-storage |
| Sources on file | 8 | 26 |
Editorial summaries
Lingo
Abbott's Lingo is an over-the-counter continuous glucose monitor for non-diabetic and wellness consumers, built on Abbott's FreeStyle Libre sensor platform (FDA 510(k) K233655, decided May 29, 2024; Class II integrated CGM): a disposable biosensor worn up to 14 days on the back of the upper arm. It is the adaptive-algorithmic end of the glucose cell, the documented contrast to Stelo's generative AI: the app's 'Lingo Count' daily glucose-spike metric with adaptive targets, food and activity logging, and rule-based personalized recommendations are adaptive-algorithmic, not generative. 'Lingo Live' is free roughly 30-minute sessions with human Abbott nutritionists, not an AI coach, and DEPLOY surfaces that distinction prominently. Pricing starts at about $54 for a 2-week single-biosensor plan, with recurring biweekly and monthly multi-sensor tiers. From Abbott (NYSE: ABT). Cap-flag: the cleared indication is adults 18+ not on insulin, explicitly NOT for diagnosis of any disease including diabetes.
Apple Watch
The Apple Watch (current Series 11 and Ultra 3, September 2025; Series 9/10 and Ultra 2 supported) is a biometric-primary smartwatch and the canonical reference of the biometric cohort, with the broadest FDA-cleared portfolio: ECG and AFib/irregular-rhythm notifications (De Novo 2018), sleep-apnea notifications (2024), and hypertension notifications (2025), plus fall and crash detection and the Vitals app. Its sensors (optical PPG, electrical ECG, temperature, accelerometer/gyro, blood-oxygen) need no subscription for the FDA-cleared medical features. Pricing anchors at about $399 for the Series base (aluminum, GPS), with the Ultra around $799 and the SE around $249 (the SE lacks ECG). A within-entity verified-vs-claimed exemplar: blood-oxygen was disabled in the US in January 2024 over the Masimo ITC ruling and re-enabled in August 2025 via a paired-iPhone calculation redesign. DEPLOY holds the claims to the specific cleared indications: these are cleared features with defined scope, not a general cardiac or sleep diagnostic.
Machine-readable: this page as markdown.